Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer.

Aim: In a prospective clinical initiative, we selected heavily pretreated head and neck carcinoma patients and assessed the clinical utility of a protein-based oncopanel for identification of potential targetable markers. Patients & methods: Tumor samples of 45 patients were evaluated using a 12-marker immunohistochemistry panel. The primary end point was the prevalence of potentially actionable markers. Results: At least one expressed marker in each case could be identified. We noted a high prevalence of EGFR (80%, 39/45) and MET (57.4%, 28/45). Three patients received oncopanel-based therapy with variable results. Conclusion: Despite the limited number of treated subjects, oncopanel analysis in end-stage head and neck cancer is operationally and technically feasible. Combination with targeted next generation sequencing might provide additional therapy options.

• Publication year

  2019

• Venue

  Immunotherapy

• Publication date

  2019-08-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt-2019-0041PMID 31462115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

  2019cited by this paper
• PROSPERO: A study to determine the utility of focused genomic profiling to guide selection of drug therapy in salivary gland cancer.

  2019cited by this paper
• Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer

  2018cited by this paper
• Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.

  2018cited by this paper
• Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

  2018cited by this paper
• Precision Medicine in Head and Neck Cancer: Myth or Reality?

  2018cited by this paper
• Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target

  2018cited by this paper
• Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfiLER study.

  2017cited by this paper
• High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

  2017cited by this paper
• Head and neck cancer: improving outcomes with a multidisciplinary approach

  2017cited by this paper
• Tumor DNA: an emerging biomarker in head and neck cancer

  2017cited by this paper
• Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma

  2016cited by this paper
• Biopanel identifies expression status of targetable proteins in sinonasal melanoma.

  2016cited by this paper
• Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma

  2016cited by this paper
• Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

  2016cited by this paper
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

  2016cited by this paper
• Managing congenital hyperinsulinism: improving outcomes with a multidisciplinary approach

  2015cited by this paper
• Molecular profiling of head and neck squamous cell carcinoma

  2015cited by this paper
• Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.

  2015cited by this paper
• KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.

  2015cited by this paper
• Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

  2015cited by this paper
• Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck

  2015cited by this paper
• Genetic mutations in head and neck cancer: utilizing existing treatments.

  2014cited by this paper
• Androgen receptor expression: prognostic value in locally advanced squamous cell carcinoma of the head and neck.

  2013cited by this paper
• Androgen receptor expression

  2013cited by this paper
• MET as a possible target for non-small-cell lung cancer.

  2013cited by this paper
• Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.

  2013cited by this paper
• Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

  2013cited by this paper
• Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival

  2012cited by this paper
• Expression of oestrogen progestrone and androgen receptors in salivary gland tumours. A review of literature.

  2012cited by this paper
• Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.

  2011cited by this paper
• Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

  2011cited by this paper
• Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

  2011cited by this paper
• Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site.

  2010cited by this paper
• Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

  2010cited by this paper
• Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

  2009cited by this paper
• Receptor tyrosine kinases in sinonasal undifferentiated carcinomas—Evaluation for EGFR, c‐KIT, and HER2/neu expression

  2009cited by this paper
• Molecular biology of head and neck cancer: risks and pathways.

  2008cited by this paper
• Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.

  2006cited by this paper
• STI‐571 (Gleevec) Potentiates the Effect of Cisplatin in Inhibiting the Proliferation of Head and Neck Squamous Cell Carcinoma In Vitro

  2006cited by this paper
• Molecular biology of squamous cell carcinoma of the head and neck

  2006cited by this paper
• Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.

  2005cited by this paper
• Profiling early head and neck cancer

  2005cited by this paper
• The National Comprehensive Cancer Network

  1998cited by this paper

• Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort

  2024cites this paper
• Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize Treatment Decisions

  2022cites this paper
• A new reliable and highly specific monoclonal antibody to detect the C‐terminal region of silencer of cytokine signaling 1

  2021cites this paper
• Cisplatin/fluorouracil/trastuzumab

  2019cites this paper